WO1995030407A1 - Magensäure-bindende kaupastillen - Google Patents
Magensäure-bindende kaupastillen Download PDFInfo
- Publication number
- WO1995030407A1 WO1995030407A1 PCT/EP1995/001493 EP9501493W WO9530407A1 WO 1995030407 A1 WO1995030407 A1 WO 1995030407A1 EP 9501493 W EP9501493 W EP 9501493W WO 9530407 A1 WO9530407 A1 WO 9530407A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pastilles
- sugar
- gelatin
- additives
- gums
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Definitions
- the invention relates to chewing lozenges based on certain natural and / or synthetic polymers containing antacids as an active ingredient.
- Tablets are pressed on tablet machines.
- the tablet mass must be prepared by mixing and granulating.
- Various authors have already dealt with granulation methods of active ingredients that are difficult to process.
- Sweets are made by mixing sucrose and glucose syrup, boiling at about 130 ° C and removing the water from the mass to 0.5 to 2% in vacuo.
- the active and aromatic substances are added to the viscous candy mass, which has cooled to about 85 ° C., and these are mixed in by kneading. In tapered rollers and other candy machines, the candy mass is drawn out into strands with constant cooling, shaped and cut. As is known, the active ingredient distribution is quite imprecise due to the toughness of the candy mass.
- REPLACEMENT SHEET Rubber pastilles are manufactured in such a way that hydrocolloids, such as e.g. B. gum arabic, together with sucrose, glucose syrup, sorbitol, xylitol or the like in water and dissolved, emulsified or suspended in this matrix the active ingredients.
- the casting compound obtained in this way is poured out into so-called powder trays. These are, for example, flat wooden boxes of approx. 80 x 40 cm, which are filled with starch, in particular maize starch.
- starch in particular maize starch.
- DE 41 40 116 AI relates to lozenges based on natural and / or synthetic polymers or fat-like substances with sugar and / or sugar substitutes, containing poly (dimethylsiloxanes) (Dimeticon, Simeticone) and a process for their preparation.
- the term "antacid” means substances that are supposed to counteract hyperacidity of gastric juice. Suitable compounds include magnesium hydroxide, magnesium oxide, magnesium carbonate, magnesium silicate, aluminum hydroxides, aluminum phosphate, magnesium aluminum silicates, hydrotalcide and magaldrate. According to Römpp, the use of earlier sodium hydrogen carbonate and calcium carbonate should be avoided, but numerous commercial products are available that contain these components at least in minor proportions.
- the object of the present invention was to use a casting process known per se from confectionery production to create a new one to provide single-dose dosage forms for antacids, which are characterized by: finest distribution of the active ingredient in the lozenge, very precise individual dosage of the active ingredient, easy handling of the active ingredient, above all pleasant intake of the drug and optimal stretching of the active ingredient in the stomach due to the slow Chew the lozenges.
- lozenges based on at least partially or completely water-soluble, natural and / or synthetic polymers, selected from gums, alginates, carrageen, starch, pectin and gelatin, which form gels or viscous solutions in aqueous systems and other auxiliaries - And additives containing antacids as an active ingredient.
- partly water-soluble, partly water-insoluble antacids can be incorporated in an extremely simple manner into pastilles based on the natural and / or synthetic polymers mentioned.
- the term pastilles and in particular the term gum pastilles include those which are produced by casting.
- the pastilles according to the present invention consist of various shaped elastic molded articles which contain antacids in a finely divided form in a mixture of hydrocolloids and other auxiliary substances and additives.
- Gum lozenges are called solid solutions, which are sucked back into liquid solutions or dispersions when sucked. With the help of the present invention it is. possible to achieve a precise individual dosage of the lozenge with relatively gentle processing of the ingredients.
- the at least partially or completely water-soluble, natural and / or synthetic polymers mentioned particularly good incorporation of the antacids is possible, since it is possible to work at relatively low temperatures.
- the method according to the invention makes it possible to produce relatively highly concentrated antacid lozenges.
- Particularly preferred natural and / or synthetic polymers in the sense of the present invention are also known under the term "hydrocolloids".
- the gums selected from gum arabic, gelatin or tragacanth are particularly preferred.
- the auxiliaries and additives are preferably selected from sugar and / or sugar substitutes, hydrogenated fats, stearic acid, paraffins, oligosaccharides, polysaccharides and / or dextran.
- lozenges Corresponding lozenges with other active ingredients are known per se in the prior art under the term "gum lozenges”. These derive their name from the raw material gum arabic processed in them. For the purposes of the present invention, too, this hydrocolloid is preferably used as the base material because it gives the lozenge good sucking and chewing properties.
- the base composition contains, in particular, flavor carriers such as sugar and / or sugar substitutes, since the patient is supposed to chew the lozenge. Accordingly, it is necessary that the lozenges taste so good that they are not refused or swallowed.
- appropriate auxiliaries such as sucrose or its substitutes fructose, hydrogenated glucose syrup, sorbitol, mannitol and / or xylitol and known sweeteners are used to improve the taste.
- taste corrections and essences, as well as essential oils can be used.
- the basic mass contains, for example, 2 to 80% by weight of the polymers, based on the total mass of the pastilles.
- An amount is particularly preferred from 10 to 60% by weight gum arabic or 10 to 60% by weight gelatin, in each case based on the total mass of the pastilles.
- lozenges contain 20 to 50% by weight of sugar and / or sugar substitutes, based on the total mass of the lozenges.
- the amount of antacid in the pastilles according to the invention can be varied within a wide range.
- the amount of antacids based on the total formulation should preferably be as large as possible, but at least have an acid-binding capacity of 20-25 meq per single dose.
- compositions such as suspensions or chewable tablets with acid-binding active ingredients, contain antacids with an acid-binding capacity of 10-25 meq. Accordingly, a particularly preferred embodiment of the present invention is to provide lozenges with an acid binding capacity of 10-40 meq.
- the polymers defined above are brought into contact with water and other auxiliary ur-d additives to form a gel or a viscous solution.
- Antacids are then suspended or dissolved in the base material thus obtained and this liquid mass is then poured into molds, dried at room temperature or at elevated temperature, in particular 40 to 70 ° C., preferably 40 to 50 ° C., removed from the mold and a final treatment fed.
- gelatin and acacia are dissolved in water and suspended with antacids.
- This medicinal mixture is poured out into so-called powder trays and, as described at the beginning, dried, separated from the powder and finished.
- the particular advantages of the pastilles according to the invention and the process for their production consist in a low temperature load on the auxiliaries and active substances, their complete homogeneity in the Casting compound which allows a high accuracy of the dosage of active substance, but above all the excellent chewability compared to tablets and the better taste, all advantages which promote patient compliance.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/737,280 US6077524A (en) | 1994-05-06 | 1995-04-20 | Gastric acid binding chewing pastilles |
EP95918575A EP0758225B1 (de) | 1994-05-06 | 1995-04-20 | Magensäure-bindende kaupastillen |
DK95918575T DK0758225T3 (da) | 1994-05-06 | 1995-04-20 | Mavesyrebindende tyggepastiller |
JP7528622A JPH09512800A (ja) | 1994-05-06 | 1995-04-20 | 胃酸結合チューイングパステル類 |
DE59501652T DE59501652D1 (de) | 1994-05-06 | 1995-04-20 | Magensäure-bindende kaupastillen |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4415999A DE4415999A1 (de) | 1994-05-06 | 1994-05-06 | Magensäurebindende Kaupastillen |
DEP4415999.4 | 1994-05-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995030407A1 true WO1995030407A1 (de) | 1995-11-16 |
Family
ID=6517455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/001493 WO1995030407A1 (de) | 1994-05-06 | 1995-04-20 | Magensäure-bindende kaupastillen |
Country Status (8)
Country | Link |
---|---|
US (1) | US6077524A (de) |
EP (1) | EP0758225B1 (de) |
JP (1) | JPH09512800A (de) |
AT (1) | ATE164061T1 (de) |
DE (2) | DE4415999A1 (de) |
DK (1) | DK0758225T3 (de) |
ES (1) | ES2115381T3 (de) |
WO (1) | WO1995030407A1 (de) |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998020860A2 (en) * | 1996-11-15 | 1998-05-22 | Fmc Corporation | Hydrocolloid delivery system |
US6531114B1 (en) | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
US6627234B1 (en) | 1998-12-15 | 2003-09-30 | Wm. Wrigley Jr. Company | Method of producing active agent coated chewing gum products |
US6586023B1 (en) | 1998-12-15 | 2003-07-01 | Wm. Wrigley Jr. Company | Process for controlling release of active agents from a chewing gum coating and product thereof |
US7935362B2 (en) | 1999-04-06 | 2011-05-03 | Wm. Wrigley Jr. Company | Over-coated product including consumable center and medicament |
RU2001126555A (ru) * | 1999-04-06 | 2003-06-20 | Вм. Ригли Дж. Компани (Us) | Составы фармацевтической жевательной резинки |
US6773716B2 (en) | 1999-04-06 | 2004-08-10 | Wm. Wrigley Jr. Company | Over-coated chewing gum formulations |
US6663849B1 (en) | 2000-09-01 | 2003-12-16 | Wm. Wrigley Jr. Company | Antacid chewing gum products coated with high viscosity materials |
US6569472B1 (en) | 2000-09-01 | 2003-05-27 | Wm. Wrigley Jr. Company | Coated chewing gum products containing antacid and method of making |
US6541048B2 (en) | 1999-09-02 | 2003-04-01 | Wm. Wrigley Jr. Company | Coated chewing gum products containing an acid blocker and process of preparing |
US6645535B2 (en) | 1999-09-02 | 2003-11-11 | Wm. Wrigley Jr. Company | Method of making coated chewing gum products containing various antacids |
US9387168B2 (en) | 1999-09-20 | 2016-07-12 | Jack Barreca | Chewing gum with tomatidine |
US9253991B2 (en) | 1999-09-20 | 2016-02-09 | Jack Barreca | Chewing gum with B vitamins |
AU3885201A (en) | 1999-09-20 | 2001-04-24 | Mastercare | Diet and weight control gum and sucker |
US6572900B1 (en) | 2000-06-09 | 2003-06-03 | Wm. Wrigley, Jr. Company | Method for making coated chewing gum products including a high-intensity sweetener |
US6444241B1 (en) | 2000-08-30 | 2002-09-03 | Wm. Wrigley Jr. Company | Caffeine coated chewing gum product and process of making |
US6579545B2 (en) | 2000-12-22 | 2003-06-17 | Wm. Wrigley Jr. Company | Coated chewing gum products containing an antigas agent |
US20040013732A1 (en) * | 2001-09-25 | 2004-01-22 | Michael Farber | Starch-based delivery system for creatine |
US7067150B2 (en) * | 2002-04-16 | 2006-06-27 | Scepter Holdings, Inc. | Delivery systems for functional ingredients |
US20080160086A1 (en) * | 2004-02-19 | 2008-07-03 | Scepter Holdings, Inc. | Delivery Systems For Calcium |
US9775376B2 (en) | 2010-12-01 | 2017-10-03 | R.J. Reynolds Tobacco Company | Smokeless tobacco pastille and moulding process for forming smokeless tobacco products |
US9220295B2 (en) | 2010-12-01 | 2015-12-29 | R.J. Reynolds Tobacco Company | Tobacco separation process for extracting tobacco-derived materials, and associated extraction systems |
US20130118512A1 (en) | 2011-11-16 | 2013-05-16 | R.J. Reynolds Tobacco Company | Smokeless tobacco products with starch component |
DE102012221900A1 (de) | 2012-11-29 | 2014-06-05 | 2LUTION GmbH | Feste Lösungen von Coffein |
US11503853B2 (en) | 2013-09-09 | 2022-11-22 | R.J. Reynolds Tobacco Company | Smokeless tobacco composition incorporating a botanical material |
US10357054B2 (en) | 2013-10-16 | 2019-07-23 | R.J. Reynolds Tobacco Company | Smokeless tobacco pastille |
US9375033B2 (en) | 2014-02-14 | 2016-06-28 | R.J. Reynolds Tobacco Company | Tobacco-containing gel composition |
US20210068447A1 (en) | 2019-09-11 | 2021-03-11 | R. J. Reynolds Tobacco Company | Pouched products with enhanced flavor stability |
US20210068446A1 (en) | 2019-09-11 | 2021-03-11 | R. J. Reynolds Tobacco Company | Oral product with cellulosic flavor stabilizer |
MX2022005285A (es) | 2019-10-31 | 2022-05-24 | Nicoventures Trading Ltd | Producto oral y metodo de fabricacion. |
US20210169123A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Pouched products with enhanced flavor stability |
US20210169121A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Liquid oral composition |
WO2021116865A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Agents for oral composition |
WO2021116824A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral product comprising a cannabinoid |
WO2021116855A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral compositions and methods of manufacture |
US20210169138A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Fibrous fleece material |
BR112022010899A2 (pt) | 2019-12-09 | 2022-09-06 | Nicoventures Trading Ltd | Produto oral com componente dissolúvel |
WO2021116919A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Fleece for oral product with releasable component |
WO2021116916A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral product with multiple flavors having different release profiles |
US20210169137A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Pouched products |
WO2021116827A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Process |
US20210169890A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Oral composition with polymeric component |
WO2021116826A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral product comprising a cannabinoid |
WO2021116854A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral products with active ingredient combinations |
US11889856B2 (en) | 2019-12-09 | 2024-02-06 | Nicoventures Trading Limited | Oral foam composition |
US20210169126A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Oral composition with salt inclusion |
US20210169129A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Lipid-containing oral composition |
WO2021116842A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral products with controlled release |
WO2021116856A2 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral products |
US20210169783A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Oral products with controlled release |
US20210169868A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Oral compositions with reduced water content |
US20210169784A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Buffered oral compositions |
US20210169785A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Oral compositions with reduced water activity |
US20210169132A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Oral composition including gels |
US11617744B2 (en) | 2019-12-09 | 2023-04-04 | Nico Ventures Trading Limited | Moist oral compositions |
US20210169786A1 (en) | 2019-12-09 | 2021-06-10 | Nicoventures Trading Limited | Oral composition with beet material |
WO2021116825A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral product |
WO2021116823A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral product |
US11793230B2 (en) | 2019-12-09 | 2023-10-24 | Nicoventures Trading Limited | Oral products with improved binding of active ingredients |
CA3159451A1 (en) | 2019-12-09 | 2021-06-17 | Savannah JOHNSON | Pouched products with heat sealable binder |
WO2021116881A1 (en) | 2019-12-09 | 2021-06-17 | Nicoventures Trading Limited | Oral product in a pourous pouch comprising a fleece material |
US11672862B2 (en) | 2019-12-09 | 2023-06-13 | Nicoventures Trading Limited | Oral products with reduced irritation |
US11712059B2 (en) | 2020-02-24 | 2023-08-01 | Nicoventures Trading Limited | Beaded tobacco material and related method of manufacture |
WO2021250516A1 (en) | 2020-06-08 | 2021-12-16 | Nicoventures Trading Limited | Effervescent oral composition comprising an active ingredient |
US20240008522A1 (en) | 2020-11-18 | 2024-01-11 | Nicoventures Trading Limited | Oral products |
US11839602B2 (en) | 2020-11-25 | 2023-12-12 | Nicoventures Trading Limited | Oral cannabinoid product with lipid component |
US20220232881A1 (en) | 2021-01-28 | 2022-07-28 | Nicoventures Trading Limited | Method for sealing pouches |
WO2022189977A1 (en) | 2021-03-09 | 2022-09-15 | Nicoventures Trading Limited | Oral products and methods of manufacture |
JP2024512417A (ja) | 2021-03-12 | 2024-03-19 | ニコベンチャーズ トレーディング リミテッド | 自己乳化系を含む経口製品 |
WO2022195562A1 (en) | 2021-03-19 | 2022-09-22 | Nicoventures Trading Limited | Extruded substrates for aerosol delivery devices |
CA3212627A1 (en) | 2021-03-19 | 2022-09-22 | Caroline W. CLARK | Beaded substrates for aerosol delivery devices |
EP4326097A1 (de) | 2021-04-22 | 2024-02-28 | Nicoventures Trading Limited | Orale zusammensetzungen und herstellungsverfahren |
CA3216322A1 (en) | 2021-04-22 | 2022-10-27 | Nicoventures Trading Limited | Effervescent oral composition |
EP4329522A1 (de) | 2021-04-30 | 2024-03-06 | Nicoventures Trading Limited | Orale produkte mit hoher dichte |
US20220354155A1 (en) | 2021-04-30 | 2022-11-10 | Nicoventures Trading Limited | Multi-compartment oral pouched product |
WO2022234522A1 (en) | 2021-05-06 | 2022-11-10 | Nicoventures Trading Limited | Oral compositions and related methods for reducing throat irritation |
WO2022264066A1 (en) | 2021-06-16 | 2022-12-22 | Nicoventures Trading Limited | Pouched product comprising dissolvable composition |
WO2022269475A1 (en) | 2021-06-21 | 2022-12-29 | Nicoventures Trading Limited | Oral product tablet and method of manufacture |
WO2022269556A1 (en) | 2021-06-25 | 2022-12-29 | Nicoventures Trading Limited | Oral products and method of manufacture |
AU2022315867A1 (en) | 2021-07-22 | 2024-01-25 | Nicoventures Trading Limited | Compositions comprising a constituent, derivative or extract of cannabis |
IL310127A (en) | 2021-07-22 | 2024-03-01 | Nicoventures Trading Ltd | Compositions comprising an ingredient, derivative or extract of cannabis |
WO2023007440A1 (en) | 2021-07-30 | 2023-02-02 | Nicoventures Trading Limited | Aerosol generating substrate comprising microcrystalline cellulose |
US20230138306A1 (en) | 2021-09-30 | 2023-05-04 | Nicoventures Trading Limited | Oral product with a basic amine and an ion pairing agent |
US20230148660A1 (en) | 2021-11-15 | 2023-05-18 | Nicoventures Trading Limited | Products with enhanced sensory characteristics |
US20230148652A1 (en) | 2021-11-15 | 2023-05-18 | Nicoventures Trading Limited | Oral products with nicotine-polymer complex |
US20230189877A1 (en) | 2021-12-20 | 2023-06-22 | Nicoventures Trading Limited | Substrate material comprising beads for aerosol delivery devices |
WO2023194959A1 (en) | 2022-04-06 | 2023-10-12 | Nicoventures Trading Limited | Pouched products with heat sealable binder |
WO2023248187A1 (en) | 2022-06-24 | 2023-12-28 | Nicoventures Trading Limited | Oral composition comprising a receptor modulator |
WO2024069542A1 (en) | 2022-09-30 | 2024-04-04 | R. J. Reynolds Tobacco Company | Method for forming reconstituted tobacco |
WO2024069544A1 (en) | 2022-09-30 | 2024-04-04 | Nicoventures Trading Limited | Reconstituted tobacco substrate for aerosol delivery device |
GB202214771D0 (en) | 2022-10-07 | 2022-11-23 | Nicoventures Trading Ltd | Oral product |
GB202214803D0 (en) | 2022-10-07 | 2022-11-23 | Nicoventures Trading Ltd | Oral product |
GB202214775D0 (en) | 2022-10-07 | 2022-11-23 | Nicoventures Trading Ltd | Oral product |
WO2024074843A1 (en) | 2022-10-07 | 2024-04-11 | Nicoventures Trading Limited | Oral product |
WO2024074839A1 (en) | 2022-10-07 | 2024-04-11 | Nicoventures Trading Limited | Oral product |
WO2024074842A1 (en) | 2022-10-07 | 2024-04-11 | Nicoventures Trading Limited | Oral product |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2033915A (en) * | 1978-10-10 | 1980-05-29 | American Home Prod | Organopolysiloxane/silica pharmaceutical compositions |
EP0286085A1 (de) * | 1987-04-08 | 1988-10-12 | Ferrosan International A/S | Eine antacide Zusammensetzung |
EP0338861A2 (de) * | 1988-04-21 | 1989-10-25 | Walton S.A. | Antacidzusammensetzungen mit längerer Verweilzeit im Magen |
WO1993010797A1 (de) * | 1991-12-05 | 1993-06-10 | Paul Bolder Arzneimittelfabrik Gmbh & Co. Kg | Dimeticon-pastillen |
WO1995005165A1 (en) * | 1993-08-13 | 1995-02-23 | Bayer Corporation | Hydrolyzed gelatin as a flavor enhancer in a chewable tablet |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2945783A (en) * | 1957-06-20 | 1960-07-19 | Reheis Company Inc | Aluminum protein antacid and process of making |
US3347682A (en) * | 1966-06-23 | 1967-10-17 | Lancet Lab Inc | Colorant tablet |
US3655866A (en) * | 1970-01-26 | 1972-04-11 | Warner Lambert Co | Sugarless gum containing dicalcium phosphate dihydrate |
AR206038A1 (es) * | 1975-03-05 | 1976-06-23 | Soreat Sa | Procedimiento de recubrimiento para mejorar la conservacion y la sobrearomatizacion de articulos de confiteria |
US4163777A (en) * | 1977-04-29 | 1979-08-07 | Lewis/Howe Company | Controlled antacid delivery form and method of treatment therewith |
CA1208558A (en) * | 1982-10-07 | 1986-07-29 | Kazuo Kigasawa | Soft buccal |
CA1258428A (en) * | 1984-06-28 | 1989-08-15 | Nalinkant C. Damani | Antacid composition |
US4971787A (en) * | 1984-08-27 | 1990-11-20 | Warner-Lambert Company | Antacid chewing gum |
DE3545090C1 (de) * | 1985-12-19 | 1987-06-25 | Capsoid Pharma Gmbh | Verfahren zur Herstellung einzeln dosierter Darreichungsformen |
US4882152A (en) * | 1985-12-20 | 1989-11-21 | Yang Robert K | Confectionery delivery system for laxatives, vitamins and antacids |
DE3914170C1 (en) * | 1989-04-28 | 1990-11-22 | Capsoid Pharma Gmbh, 7128 Lauffen, De | Pastille prepn. contg. vitamin(s) etc. - by dosing concave mould with liq. sol or gel mixt. contg. active ingredient, gelatin and water |
US5591473A (en) * | 1993-07-08 | 1997-01-07 | Mcardle; Blaise | Protein-polysaccharide complex composition, method of preparation and use |
-
1994
- 1994-05-06 DE DE4415999A patent/DE4415999A1/de not_active Withdrawn
-
1995
- 1995-04-20 EP EP95918575A patent/EP0758225B1/de not_active Expired - Lifetime
- 1995-04-20 AT AT95918575T patent/ATE164061T1/de not_active IP Right Cessation
- 1995-04-20 US US08/737,280 patent/US6077524A/en not_active Expired - Lifetime
- 1995-04-20 JP JP7528622A patent/JPH09512800A/ja active Pending
- 1995-04-20 ES ES95918575T patent/ES2115381T3/es not_active Expired - Lifetime
- 1995-04-20 WO PCT/EP1995/001493 patent/WO1995030407A1/de active IP Right Grant
- 1995-04-20 DE DE59501652T patent/DE59501652D1/de not_active Expired - Fee Related
- 1995-04-20 DK DK95918575T patent/DK0758225T3/da active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2033915A (en) * | 1978-10-10 | 1980-05-29 | American Home Prod | Organopolysiloxane/silica pharmaceutical compositions |
EP0286085A1 (de) * | 1987-04-08 | 1988-10-12 | Ferrosan International A/S | Eine antacide Zusammensetzung |
EP0338861A2 (de) * | 1988-04-21 | 1989-10-25 | Walton S.A. | Antacidzusammensetzungen mit längerer Verweilzeit im Magen |
WO1993010797A1 (de) * | 1991-12-05 | 1993-06-10 | Paul Bolder Arzneimittelfabrik Gmbh & Co. Kg | Dimeticon-pastillen |
WO1995005165A1 (en) * | 1993-08-13 | 1995-02-23 | Bayer Corporation | Hydrolyzed gelatin as a flavor enhancer in a chewable tablet |
Also Published As
Publication number | Publication date |
---|---|
DE4415999A1 (de) | 1995-11-09 |
JPH09512800A (ja) | 1997-12-22 |
EP0758225B1 (de) | 1998-03-18 |
ES2115381T3 (es) | 1998-06-16 |
DK0758225T3 (da) | 1998-12-07 |
DE59501652D1 (de) | 1998-04-23 |
EP0758225A1 (de) | 1997-02-19 |
US6077524A (en) | 2000-06-20 |
ATE164061T1 (de) | 1998-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0758225B1 (de) | Magensäure-bindende kaupastillen | |
DE69821553T2 (de) | Granulatzubereitung enthaltend Simethicon und granuliertes wasserfreies Calciumphosphat | |
DE69920344T2 (de) | Verwendung eines Acrylsäure-Typ Polymeres als Desintegrationsmittel, Vefahren zur Herstellung von Tabletten und hergestellte Tabletten | |
DE69531788T2 (de) | Verbessertes bioadhäsives pharmazeutisches abgabesystem | |
DE4201172C1 (en) | Pellets contg. Aloe vera extract - useful, e.g. as antiinflammatory of antibiotic agents, or for treating gastric ulcers | |
DE2323686A1 (de) | Arzneimittelzubereitungsform mit langzeitwirkung und verfahren zu ihrer herstellung | |
DD292837A5 (de) | Verfahren zur herstellung von cholestyramin-tabletten | |
DE2813146A1 (de) | Tablettieren von mikrokapseln | |
DE2020620B2 (de) | Trager fur das unmittelbare Komprimieren von Tabletten | |
EP3389389B1 (de) | Giessmasse und verfahren für die herstellung von gelatineprodukten | |
EP0615450B1 (de) | Dimeticon-pastillen | |
DE2951077C2 (de) | ||
DE2854651C2 (de) | ||
CN1145586A (zh) | 含药物/聚合物复合物的味掩蔽组合物 | |
EP3609350A1 (de) | Gelatineprodukt mit einer kernkomponente und verfahren zu dessen herstellung | |
EP0804152B1 (de) | Lactulose-pastillen | |
DE602004008737T2 (de) | Chondroitinsulfat enthaltende Zusammensetzung | |
EP0620727B1 (de) | Pflanzenwirkstoffextrakt enthaltende kryopelletierte formkörper und ihre pharmazeutische oder kosmetische verwendung | |
EP1135147B1 (de) | Verfahren zur herstellung von arzneimitteln in fester darreichungsform aus pflanzlichen extrakten | |
WO2001016218A1 (de) | Schnellzerfallende pellets auf der basis von chitosan | |
DE1617638A1 (de) | Tablettenbindemittel | |
DE3914170C1 (en) | Pastille prepn. contg. vitamin(s) etc. - by dosing concave mould with liq. sol or gel mixt. contg. active ingredient, gelatin and water | |
DE3790355C2 (de) | Verfahren zur Herstellung magensalzsäureneutralisierender pharmazeutischer Präparate mit großer säurebindender Kapazität, verzögerter Wirkungsdauer und vergrößerter Bioverfügbarkeit | |
WO2010102841A1 (de) | Verpressbares tablettenmaterial mit ölhaltigem wirkstoff, tablette sowie verfahren und vorrichtung zu deren herstellung | |
DE2333217A1 (de) | Antacide tablettenmasse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995918575 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995918575 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08737280 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995918575 Country of ref document: EP |